Interleukin Enhancer-binding Factor 3/NF110 Is a Target of YM155, a Suppressant of Survivin

Interleukin enhancer-binding factor 3 functions as a liver receptor homologue-1 co-activator in synergy with the nuclear receptor co-activators PRMT1 and PGC-1α

(2011) Masae Ohno et al.   BIOCHEMICAL JOURNAL

TLS and PRMT1 synergistically coactivate transcription at the survivin promoter through TLS arginine methylation

(2010) Kun Du et al.   BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS

Survivin: A new target for anti-cancer therapy

(2009) Bríd M. Ryan et al.   CANCER TREATMENT REVIEWS

Phase I Study of YM155, a Novel Survivin Suppressant, in Patients with Advanced Solid Tumors

(2009) T. Satoh et al.   CLINICAL CANCER RESEARCH

Multicenter Phase II Trial of YM155, a Small-Molecule Suppressor of Survivin, in Patients With Advanced, Refractory, Non–Small-Cell Lung Cancer

(2009) Giuseppe Giaccone et al.   JOURNAL OF CLINICAL ONCOLOGY

Tankyrase inhibition stabilizes axin and antagonizes Wnt signalling

(2009) Shih-Min A. Huang et al.   NATURE

Identification of the cellular targets of bioactive small organic molecules using affinity reagents

(2008) Benjamin J. Leslie et al.   CHEMICAL SOCIETY REVIEWS

Radiosensitizing Effect of YM155, a Novel Small-Molecule Survivin Suppressant, in Non-Small Cell Lung Cancer Cell Lines

(2008) T. Iwasa et al.   CLINICAL CANCER RESEARCH

Survivin: Key Regulator of Mitosis and Apoptosis and Novel Target for Cancer Therapeutics

(2008) A. C. Mita et al.   CLINICAL CANCER RESEARCH

Confirmation of Gene Expression-Based Prediction of Survival in Non-Small Cell Lung Cancer

(2008) N. L. Guo et al.   CLINICAL CANCER RESEARCH

Phase I and Pharmacokinetic Study of YM155, a Small-Molecule Inhibitor of Survivin

(2008) Anthony W. Tolcher et al.   JOURNAL OF CLINICAL ONCOLOGY

Nuclear Factor 45 (NF45) Is a Regulatory Subunit of Complexes with NF90/110 Involved in Mitotic Control

(2008) D. Guan et al.   MOLECULAR AND CELLULAR BIOLOGY